MetaCap

Advanced Biomed Inc. (ADVB)

NASDAQ: ADVBHealth CareMedical SpecialitiesUSD

1.65-0.10 (-5.71%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ADVB stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$5.03
52-week range
1.58 – 24.23
Day range
1.58 – 1.76
Volume / Avg
16.71K / 88.38K
Beta
—

52-week range

$1.58$24.23

ADVB stock today

Advanced Biomed (ADVB) closed at $1.65 on Nov 20, down 5.71% (-$0.10), versus the S&P 500's 3.70% decline. Trading was light, with 16.71K shares changing hands, about 19% of the average daily volume. Shares are 93.2% below their 52-week high of $24.23, set on Jul 24, 2026 and 4.4% above the 52-week low of $1.58, near the bottom of the past year's range.

ADVB is down 71.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 77.8%. Advanced Biomed has posted a net loss over the last twelve months (EPS of -$5.03), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Advanced Biomed

Company profile

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients.

Industry
Medical Specialities
CEO
Mr. Xiaomin Chen Ph.D.
Headquarters
New York, NY
Employees
31
IPO year
2025

Financial highlights

Full financials

In fiscal 2026, Advanced Biomed generated $127,637 in revenue. Net income was $6.7 million, for a net margin of 5231.3%. Operating margin was -4883.8%.

Advanced Biomed annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024
Revenue$127.64K——
Growth———
Net income$6.68M$-3.26M$-2.78M
EPS (diluted)$5.33$-3.18$-0.14

Earnings

Earnings history
Last reported (Sep/2026)
Nov 18, 2026
EPS actual vs est.
$-0.60 vs —

Advanced Biomed peers

Health Care sector
ADVB peer companies
CompanyPrice% ChgMarket capCompare
BGLCBioNexus Gene Lab Corp0.680.00%$1.99Mvs ADVB
ACONAclarion Inc.1.22-13.92%$3.52Mvs ADVB
AMSAmerican Shared Hospital Services1.00-4.76%$6.67Mvs ADVB
MDXHMDxHealth SA0.1074-8.52%$10.25Mvs ADVB
SERASera Prognostics Inc. Class A1.81-4.23%$71.98Mvs ADVB
BDSXBiodesix Inc.7.56-8.92%$83.83Mvs ADVB
XGNExagen Inc.3.61-5.00%$92.10Mvs ADVB
KEQUKewaunee Scientific Corporation33.55-2.75%$97.14Mvs ADVB

Indexes, lists and sector

Advanced Biomed stock FAQ

What is Advanced Biomed's stock price today?

ADVB last traded at $1.65 as of Nov 20, 4:00 PM EST, down 5.71% on the day. Prices are delayed at least 15 minutes.

Does Advanced Biomed pay a dividend?

No. Advanced Biomed does not currently pay a regular cash dividend.

Who is Advanced Biomed's CEO?

Mr. Xiaomin Chen Ph.D. is the chief executive officer of Advanced Biomed Inc., which has about 31 employees.

Has ADVB ever split its stock?

Yes. The most recent ADVB stock split was a 1-for-20 split on Feb 20, 2026.

What is the ADVB 52-week high?

The 52-week high for ADVB is $24.23 and the 52-week low is $1.58. The stock is currently 93.2% below its high.

Compare ADVB